Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
    Research/Science 10/15/2025

    New to PP405? There is a guide in the encyclopedia. Read the guide →
    At a glance
    In this general discussion post, the primary subjects mentioned are the tone is 😐 neutral with promising results.

    Other terms

    Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results
      PP405 in Alopecia: An Emerging Molecule Worth Investigating

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      New Therapeutics in the Management of Androgenetic Alopecia

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
      Review of the 2024 American Academy of Dermatology Annual Meeting

      research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting

      April 2024
      This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.
      Estrogen Functions in Skin and Skin Appendages

      research Oestrogen functions in skin and skin appendages

      68 citations , June 2005 in “Expert Opinion on Therapeutic Targets”
      This review discusses the influence of oestrogens on various skin components and highlights their modulatory roles and receptor pathways, but it reports no new clinical results.